Edition:
United States

West Pharmaceutical Services Inc (WST)

WST on New York Consolidated

92.28USD
19 Oct 2017
Change (% chg)

$-0.13 (-0.14%)
Prev Close
$92.41
Open
$92.53
Day's High
$92.84
Day's Low
$91.32
Volume
500,417
Avg. Vol
378,002
52-wk High
$99.91
52-wk Low
$70.17

Summary

Name Age Since Current Position

Patrick Zenner

70 2015 Non-Executive Independent Chairman of the Board

Eric Green

47 2015 President, Chief Executive Officer, Director

William Federici

57 2017 Chief Financial Officer, Senior Vice President, Treasurer

Annette Favorite

52 2015 Chief Human Resource Officer, Senior Vice President

George Miller

62 2015 Senior Vice President, General Counsel, Corporate Secretary

Karen Flynn

54 2016 Senior Vice President and Chief Commercial Officer

David Montecalvo

51 2016 Senior Vice President - Global Operations and Supply Chain

Eric Resnick

53 2016 Chief Technology Officer, Vice President

Daniel Malone

55 2011 Vice President, Corporate Controller

Michael Anderson

61 2016 Vice President, Treasurer

Paolo Pucci

56 2016 Director

Mark Buthman

56 2011 Independent Director

William Feehery

46 2012 Independent Director

Thomas Hofmann

65 2007 Independent Director

Paula Johnson

57 2005 Independent Director

Deborah Keller Tanner

54 2017 Independent Director

Myla Lai-Goldman

59 2014 Independent Director

Douglas Michels

60 2011 Independent Director

John Weiland

61 2007 Independent Director

Quintin Lai

2016 IR Contact Officer

Biographies

Name Description

Patrick Zenner

Mr. Patrick J. Zenner is Non-Executive Independent Chairman of the Board of West Pharmaceutical Services, Inc. Mr. Zenner was elected Chairman of the Board effective July 1, 2015. He retired from Hoffmann-La Roche Inc., North America—the prescription drug unit of the Roche Group, a leading research-based healthcare enterprise—in 2001, where he served as President and Chief Executive Officer from 1993 to 2001. He served as Interim Chief Executive Officer of CuraGen Corporation from May 2005 through March 2006. Since then, Mr. Zenner was a director and Chairman of the Board of Exact Sciences Corporation until July 2010, and served as its Interim CEO from July 2007 to March 2008. Currently, Mr. Zenner serves as Chairman of the Board and a director of ArQule, Inc. Mr. Zenner provides more than 40 years of experience and expertise in the pharmaceutical industry to the Board. Since retiring from Hoffmann-La Roche, Mr. Zenner has devoted his considerable industry expertise and corporate governance knowledge to small and early-stage pharmaceutical and technology companies in various capacities, including board member, chairman and interim CEO.

Eric Green

Mr. Eric Mark Green is President, Chief Executive Officer, Director of the Company. Prior to joining the Company, Mr. Green worked at Sigma-Aldrich Corporation, where he served as Executive Vice President and President of the company’s Research Markets business unit since 2013. Mr. Green has significant public company experience having served as a corporate officer and member of the senior executive team of Sigma-Aldrich prior to joining the Company. Sigma-Aldrich is a leading life science and technology company focused on human health and safety. Mr. Green has had research and development responsibility and managed a $1.4 billion business unit—the largest at that company. Prior to that he held key positions of increasing responsibility, including international sales and operations, corporate strategic planning and positions in the UK, Ireland and Canada. Mr. Green has a chemistry degree and masters of business administration.

William Federici

Mr. William J. Federici is Chief Financial Officer, Senior Vice President and Treasurer of the company. He was National Industry Director for Pharmaceuticals of KPMG LLP (accounting firm) from June 2002 until August 2003 and, prior thereto, an audit partner with Arthur Andersen, LLP.

Annette Favorite

Ms. Annette Favorite is Senior Vice President and Chief Human Resources Officer of West Pharmaceutical Services, Inc. Prior to joining West, she spent more than 25 years at IBM Corporation, an information technology services company, in a number of strategic and global human resources roles. Most recently, she served as Vice President, Global Talent Management.

George Miller

Mr. George Lloyd Miller, J.D., is Senior Vice President, General Counsel, Corporate Secretary of West Pharmaceutical Services, Inc. Previously, he served as Senior Vice President, General Counsel and Corporate Secretary for Sigma-Aldrich Corporation from 2009 to 2015. Prior to working at Sigma-Aldrich, he held senior legal positions with Novartis AG, a global healthcare company.

Karen Flynn

Ms. Karen A. Flynn is Senior Vice President and Chief Commercial Officer of the Company. She was President, Pharmaceutical Packaging Systems from October 2014 to January 2016, President, Pharmaceutical Packaging Systems Americas Region from June 2012 to October 2014, and Vice President, Sales from May 2008 to June 2012. From 2000 to 2008, she worked in Sales Management, most recently as Vice President, Global Accounts, for Catalent (formerly a business segment of Cardinal Health). Prior thereto, she held various positions at West, including Quality, Research and Development, and Sales.

David Montecalvo

Mr. David A. Montecalvo serves as Senior Vice President - Global Operations and Supply Chain of the Company. Prior to joining West, he served in a number of senior leadership roles at Medtronic plc, including Vice President, Contract Manufacturing Operations, for the company's Restorative Therapies Group, and Vice President, Business Operations Integration, where he was responsible for directing and leading the global operations integration of Covidien plc into Medtronic. Prior thereto, he held senior operations and product development roles at Urologix, Inc. and LecTec Corporation.

Eric Resnick

Mr. Eric Resnick is Vice President and Chief Technology Officer of the company. Previously, he served as Vice President and General Manager of Integrated Packaging and Delivery within West's Innovation and Technology Team and President Proprietary Products - Pharmaceutical Delivery Systems from March 2015 until March 2016. He served as Vice President Research and Development and Self-Injection Systems from March 2014 until March 2015, and Vice President and General Manager of West's Contract Manufacturing Delivery Devices division from 2008 until March 2014. Prior thereto, he held various positions of increasing responsibility since joining The Tech Group in 2001. Prior to joining West, he held engineering and operating roles with Eastman Kodak Company and Ortho Clinical Diagnostics.

Daniel Malone

Mr. Daniel Malone is Vice President and Corporate Controller of the Company, since August 2011. He was Vice President of Finance, Pharmaceutical Packaging Systems Americas Region from September 2008 to August 2011 and Director of Financial and Management Reporting from October 1999 to September 2008.

Michael Anderson

Mr. Michael A. Anderson is Vice President and Treasurer of the Company, since June 2001. He was Finance Director, Drug Delivery Systems Division from October 1999 to June 2001, Vice President, Business Development from April 1997 to October 1999 and Director of Taxes from July 1992 to April 1997. He retired from West as of December 31, 2016.

Paolo Pucci

Mr. Paolo Pucci serves as Director of the company. Mr. Pucci is Chief Executive Officer of ArQule, Inc., a biopharmaceutical company engaged in the research and development of targeted therapeutics. Prior to joining ArQule in 2008, Mr. Pucci worked at Bayer A.G., where he served in a number of leadership capacities including Senior Vice President of the Global Specialty Medicine Business Unit and was a member of the Bayer Pharmaceuticals Global Management Committee. Mr. Pucci provides a wealth of knowledge to our Board regarding biopharmaceutical markets and experience as a chief executive officer of a publicly-traded company. His international background also adds to the diverse knowledge base of our Board.

Mark Buthman

Mr. Mark A. Buthman is an Independent Director of West Pharmaceutical Services, Inc. Mr. Buthman retired from Kimberly-Clark Corporation in December 2015, where he was Executive Vice President and Chief Financial Officer from January 2003 to April 2015. He held positions of increasing responsibility in finance, strategy and operations after joining Kimberly-Clark in 1982. Mr. Buthman is a Board member of IDEX Corporation, Vice Chairman of the Board of Directors of Pavillon, International and a member of the University of Iowa, Tippie College of Business Advisory Board. In addition to his financial and accounting experience while Chief Financial Officer at Kimberly-Clark, a global producer of branded products for the consumer, professional and healthcare markets, Mr. Buthman was responsible for real estate, investor relations, information technology, finance and accounting shared services and global procurement for the corporation. Throughout his tenure at Kimberly-Clark, he served in a wide range of leadership roles in the areas of analysis, strategy and mergers and acquisitions.

William Feehery

Dr. William F. Feehery, Ph.D., is an Independent Director of West Pharmaceutical Services, Inc. Dr. Feehery has been President of Industrial Biosciences at E. I. du Pont de Nemours and Company since November 2013. He served as Global Business Director, DuPont Photovoltaic Solutions and previously as Global Business Director, Electronics Growth Businesses and as President of DuPont Displays, Inc. since joining DuPont in 2002. Prior to joining DuPont, he was engaged in venture capital and was a management consultant for the Boston Consulting Group. Dr. Feehery brings extensive global public company leadership experience to the Board, having served in leadership roles throughout the DuPont organization, a provider of innovative products and services for markets including agriculture, nutrition, electronics, communications, safety and protection, home and construction, transportation and apparel. His experience includes direct responsibility for business operations in over 20 countries and leading a global manufacturing business. In addition, Dr. Feehery brings considerable technical experience with a Ph.D. in chemical engineering and over ten years of experience in the technology industry.

Thomas Hofmann

Mr. Thomas W. Hofmann is an Independent Director of West Pharmaceutical Services, Inc. Mr. Hofmann retired from Sunoco, Inc. an oil refining and marketing company—in 2008, where he was Senior Vice President and CFO from January 2002 to December 2008. Mr. Hofmann served Sunoco in various other senior Management roles since he joined in 1977. Mr. Hofmann provides substantial financial, corporate governance and Management experience with expertise in all areas of finance—including tax, accounting, auditing, treasury, investor relations and budgeting. He is well-versed in strategic planning, risk-management and capital-market issues. During a distinguished career with Sunoco, Inc., Mr. Hofmann was involved in a number of unique transactions, including significant acquisitions and divestitures.

Paula Johnson

Dr. Paula A. Johnson, M.D., MPH., is an Independent Director of West Pharmaceutical Services, Inc. Dr. Johnson has been President of Wellesley College since July 2016. Before joining Wellesley, Dr. Johnson founded and served as the inaugural Executive Director of the Connors Center for Women’s Health and Gender Biology, as well as Chief of the Division of Women’s Health at Brigham and Women’s Hospital. A cardiologist, Dr. Johnson was the Grace A. Young Family Professor of Medicine in the Field of Women’s Health—an endowed professorship named in honor of her mother—at Harvard Medical School. She was also Professor of Epidemiology at the Harvard T.H. Chan School of Public Health. Dr. Johnson brings a wealth of leading healthcare expertise to our Board. She is a nationally recognized expert in cardiology and women’s and minority healthcare issues. In her role as Executive Director of the Connors Center for Women’s Health and Gender Biology and as Chief of the Division of Women’s Health at Brigham and Women’s Hospital, and a Professor of Medicine at Harvard Medical School and Professor of Epidemiology at the T.H. Chan Harvard School of Public Health, Dr. Johnson has built a novel, interdisciplinary research, education, clinical and policy program in women’s health whose mission is to improve the health of women and to transform their medical care. Dr. Johnson is the recipient of many awards recognizing her contributions to women’s and minority health and is featured as a national leader in medicine by the National Library of Medicine and is a member of the National Academy of Medicine. She has an extensive background in quality and safety in healthcare and in public health systems.

Deborah Keller Tanner

Ms. Deborah L. Keller Tanner is Independent Director of the company. She serves as a Principal at Black Frame Advisors, LLC, and recently retired as Chief Executive Officer of Covance Drug Development, a business segment of Laboratory Corporation of America Holdings. Prior to serving as CEO, Ms. Keller spent more than 28 years at Covance in a number of leadership roles, including Corporate Executive Vice President and Group President of Research and Development Laboratories, Corporate Senior Vice President and President of Discovery and Translational Services, and Vice President of Analytical Services inEurope. Prior to joining Covance, Ms. Keller began her career as an Analytical Chemist at Perrigo Company.

Myla Lai-Goldman

Dr. Myla P. Lai-Goldman, M.D., is an Independent Director of West Pharmaceutical Services, Inc. Dr. Lai-Goldman has been Chief Executive Officer and President of GeneCentric Diagnostics, Inc.—a molecular diagnostics company—since June 2011 and serves as director for the company. She is also managing partner of Personalized Science, LLC, a clinical diagnostics consulting company that she founded in 2008. Previously, Dr. Lai-Goldman was Chief Executive Officer and Chief Scientific Officer of CancerGuide Diagnostics, Inc. Before joining CancerGuide Diagnostics, she held various roles—including Executive Vice President, Chief Medical Officer and Chief Scientific Officer—at Laboratory Corporation of America Holdings and its predecessor company, Roche Biomedical Laboratories. Additionally, Dr. Lai-Goldman has been a venture partner at Hatteras Venture Partners since August 2011.

Douglas Michels

Mr. Douglas A. Michels is an Independent Director of West Pharmaceutical Services, Inc. Mr. Michels serves as President and Chief Executive Officer of OraSure Technologies, Inc. and a member of the OraSure Board of Directors, positions he has held since June 2004. In February 2010, Mr. Michels was appointed to the Presidential Advisory Council on HIV/AIDS. He previously served on the Board of the National Blood Foundation, the Board of the National Committee for Quality Health Care and the Coalition to Protect America’s Health Care. Mr. Michels brings considerable expertise and executive leadership skills in the pharmaceutical, medical device and diagnostic industry having spent 12 years with OraSure Technologies, Inc., 19 years with Johnson & Johnson and seven years with Abbott Laboratories.

John Weiland

Mr. John H. Weiland is an Independent Director of West Pharmaceutical Services, Inc. Mr. Weiland has been President and Chief Operating Officer of C. R. Bard, Inc.—a medical-device company—since August 2003. At Bard, he served as Group President from April 1997 to August 2003 and Group Vice President from March 1996 to April 1997. Mr. Weiland was elected to the Bard Board of Directors in April 2005 and became Vice Chairman of the Board in 2016. He received the prestigious Horatio Alger Award in 2012 and serves as a director of the Horatio Alger Association. Mr. Weiland has considerable expertise with over 30 years in the healthcare industry. He brings executive leadership in medical-device company operations and significant international business expertise to the Board. As President and Chief Operating Officer at C.R. Bard, Inc., Mr. Weiland has responsibility for all of its business operations.

Quintin Lai